Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Poniatowa – page 24

827 clinical trials in Poniatowa, Poland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Poniatowa at a glance
827
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

827 trials in Poniatowa

Open in trial search

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Rezpegaldesleukin (NKTR-358) in Patients Aged 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rezpegaldesleukin
  • Sponsor:Nektar Therapeutics

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Rezpegaldesleukin (NKTR-358) in Patients Aged ≥12 Years with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rezpegaldesleukin
  • Sponsor:Nektar Therapeutics

Small cell lung cancer+2

Not yet recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BioNTech SE

Cardiovascular disorder+3

Not yet recruiting

Study of Once‑Weekly Eloralintide (LY3841136 Sodium) in Adults with Obesity or Overweight, Type 2 Diabetes, and High Cardiovascular Risk

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

Hypercholesterolaemia

Not yet recruiting

Effect of laroprovstat/rosuvastatin combination versus laroprovstat, rosuvastatin, and placebo on LDL‑C in hypercholesterolemia patients not previously treated with lipid‑lowering therapy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Obesity+1

Not yet recruiting

Phase 3 Double‑Blind Study of Olatorepatide for Weight Loss in Adults with Overweight or Obesity Without Diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Olatorepatide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Colitis ulcerative

Not yet recruiting

Phase 2b Study of ATH-063 in Adults with Biologic‑Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:ATH-063 hydrochloride
  • Sponsor:Athos Therapeutics Inc.

Type 2 diabetes mellitus+2

Not yet recruiting

Efficacy and Safety of Olatorepatide in Adults with Overweight or Obesity and Type 2 Diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Olatorepatide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Dermatitis atopic

Not yet recruiting

A Phase 2b Study Evaluating the Efficacy and Safety of ENV-294 in Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:ENV-294
  • Sponsor:Enveda Therapeutics Inc.

Type 2 diabetes mellitus

Not yet recruiting

Study of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Poniatowa

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical trials focusing on hyperlipidemia management, specifically targeting patients at high and very high cardiovascular risk. The research evaluates the effectiveness of rosuvastatin treatments and combination therapies in achieving optimal LDL-C reduction.

  • Lipid Management
  • Cardiovascular Risk Prevention
  • Combination Therapy Assessment

These studies aim to establish more effective treatment protocols for patients requiring intensive lipid-lowering therapy.

02 Rheumatology Studies

Comprehensive research evaluating biosimilar treatments for rheumatoid arthritis. The trials compare the efficacy of new biosimilar options with established treatments, focusing on patients with moderate to severe disease conditions.

  • Biosimilar Development
  • Treatment Efficacy Assessment
  • Immunogenicity Studies

This research aims to expand treatment options while maintaining high efficacy standards in rheumatoid arthritis management.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.